Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland‐type lung adenocarcinoma diagnosed due to esophageal stricture: A case report. Issue 18 (8th August 2021)

• Record Type: Journal Article
• Authors: Kawakado, Keita; Tamura, Tomoki; Nakanishi, Masamoto; Makimoto, Go; Sato, Yumiko; Kuyama, Shoichi
• Is Part Of: Thoracic cancer. Volume 12:Issue 18(2021)
• Page Start: 2513
• Page End: 2516
• Publication Date: 2021-08-08
• Subjects: carboplatin -- case report -- pembrolizumab -- pemetrexed -- primary salivary gland‐type tumor of the lung; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.14100
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract: Primary salivary gland‐type tumors of the lung are rare, accounting for <1% of all lung tumors. There are few reports on chemotherapy for the treatment of primary salivary gland‐type tumors of the lung. The patient in this report was a 71‐year‐old woman who presented with a chief complaint of dysphagia. Upper gastrointestinal endoscopy revealed an esophageal stricture, but biopsy showed no malignancy. Chest computed tomography (CT) showed carcinomatous lymphangiomatosis and a nodule in the right lung. Bronchoscopy showed a rough mucous membrane of the central bronchi, while biopsy showed adenocarcinoma. The patient was diagnosed with bronchogenic adenocarcinoma and received carboplatin, pemetrexed, and pembrolizumab, which alleviated the esophageal stricture and cancerous lymphangiopathy. However, the adenocarcinoma progressed, and she subsequently received several rounds of chemotherapy. One year after diagnosis, the patient died, and pathological autopsy revealed primary salivary gland‐type tumors of the lung. Abstract : Lung adenocarcinoma was diagnosed in this patient who subsequently received carboplatin, pemetrexed and pembrolizumab. The carcinomatous lymphangiomatosis improved. Autopsy revealed the tumor was primary salivary gland‐type lung adenocarcinoma.